Makes vaccines, including the smallpox/mpox vaccine and travel vaccines such as rabies and cholera.
Makes vaccines, including the smallpox/mpox vaccine and travel vaccines such as rabies and cholera.
A big share comes from government orders for the smallpox and mpox vaccine, awarded as contracts that deliver in lumps; travel vaccines sold to clinics are steadier. Its travel vaccines were bought from other pharma firms, GSK and Emergent, rather than developed in-house.
Moat: narrow (regulatory licence, IP / patents). One of few approved mpox/smallpox vaccine makers with long-term government stockpile contracts.
Headquarters: Hellerup, Denmark · Founded: 1994 · Employees: 1,795
Size Bavarian Nordic A/S (BAVA.CO) is a Denmark Health Care company (Biotechnology) with a market value of $2.82B, the 29th largest of 60 Denmark companies the cockpit tracks. Shares closed at DKK 243.00 on 18 Nov 2026.
Performance Over six months the shares gained 23.4%, against -3.3% for the median peer and +6.3% for the Denmark market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue fell 8.2% over the last twelve months (peer median +12.3%); the operating margin is 18.3% (peer median -2.6%).
Valuation It trades at 16.6× forward earnings against a peer median of 30.6× (2nd cheapest of 9).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is -32 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.5 points above its cost of capital (5.0% WACC).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | DKK 6.30B | DKK 6.17B | DKK 5.71B | DKK 7.06B | DKK 3.15B |
| Revenue growth | — | +8% | -19% | +124% | — |
| Gross profit | DKK 3.15B | DKK 2.92B | DKK 2.73B | DKK 4.52B | DKK 1.65B |
| EBITDA | DKK 1.89B | DKK 1.64B | DKK 1.56B | DKK 2.05B | DKK 328M |
| Net income | DKK 897M | DKK 1.38B | DKK 988M | DKK 1.48B | -DKK 347M |
| Free cash flow | DKK 847M | DKK 2.52B | DKK 1.87B | DKK 977M | -DKK 141M |
| Capital expenditure | DKK 340M | DKK 1.36B | DKK 1.69B | DKK 977M | DKK 1.38B |
| Total debt | DKK 123M | DKK 131M | DKK 128M | DKK 145M | DKK 1.19B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Bavarian Nordic A/S BAVA.CO | $2.82B | +23% | -8% | 18% | 16.6× | -4.3% |
| Emergent BioSolutions EBS | n/a | -33% | n/a | n/a | n/a | n/a |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 9.7× | -4.8% |
| GSK GSK.L | $97.9B | -3% | +4% | 25% | 10.4× | -0.1% |
| Valneva VLA.PA | $508M | -6% | -27% | -87% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BAVA.CO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.4% | -5.8% | 7th highest of 21 |
| 6-month return | +23.4% | -3.3% | 7th highest of 21 |
| Distance from 52-week high | -5.5% | -31.6% | 2nd highest of 21 |
| Revenue growth (TTM) | -8.2% | +12.3% | 4th lowest of 17 |
| Operating margin | 18.3% | -2.6% | 4th highest of 18 |
| Forward P/E | 16.6× | 30.6× | 2nd cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | -4.3% | 10.8% | least demanding of 7 |
| Growth delivered (Del g) | +27.4% | +22.7% | 4th highest of 7 |
| Hurdle (Req g minus delivered) | -31.7 pp | -20.1 pp | 4th least demanding of 7 |
| ROIC minus cost of capital | +3.5 pp | -9.4 pp | 4th highest of 18 |
| EV / EBITDA | 8.7× | 53.7× | cheapest of 6 |
| Net debt / EBITDA | -1.5× | 1.1× | least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.82B | +23% | -8% | 18% | 16.6× | -4.3% | +27.4% |
| Zai Lab 9688.HK | Hong Kong | $2.79B | +23% | 0% | -63% | n/a | n/a | n/a |
| XtalPi 2228.HK | Hong Kong | $2.87B | -34% | +4% | -127% | n/a | n/a | n/a |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.72B | -7% | +20% | -3% | n/a | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.94B | +68% | +37% | 21% | 66.6× | n/a | n/a |
| Denali Therapeutics DNLI | United States | $2.95B | -2% | n/a | -2,488% | n/a | n/a | n/a |
| HLB 028300.KS | South Korea | $2.69B | -49% | +26% | -96% | n/a | n/a | n/a |
| Dyne Therapeutics DYN | United States | $2.97B | -10% | n/a | n/a | n/a | n/a | n/a |
| Telix Pharmaceuticals TLX.AX | Australia | $2.99B | -2% | +27% | -1% | 34.5× | n/a | n/a |
| MBX Biosciences MBX | United States | $2.65B | +70% | n/a | n/a | n/a | n/a | n/a |
| ADMA Biologics ADMA | United States | $3.01B | +58% | +6% | 45% | 16.7× | -0.8% | +64.6% |
| Xencor XNCR | United States | $2.58B | +204% | +34% | -73% | n/a | n/a | n/a |
| Xeris Biopharma XERS | United States | $3.10B | +173% | +38% | 13% | 49.7× | 29.5% | +70.2% |
| Xiamen Amoytop Biotech 688278.SS | China | $2.56B | -27% | +18% | 27% | 15.0× | -0.6% | +36.0% |
| Virbac VIRP.PA | France | $3.20B | -4% | +4% | 15% | 16.6× | 5.8% | +9.4% |
| Hualan Biological Engineering 002007.SZ | China | $3.20B | -17% | -11% | 17% | 26.7× | 15.8% | -1.8% |
| Walvax Biotechnology 300142.SZ | China | $2.48B | -26% | -23% | 5% | 348.7× | 29.5% | -3.8% |
| Enliven Therapeutics ELVN | United States | $3.30B | +7% | n/a | n/a | n/a | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.32B | -25% | -54% | -6,983% | n/a | n/a | n/a |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.33B | -59% | 0% | -25% | n/a | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.46B | +111% | +51% | -61% | n/a | n/a | n/a |